| Abstrakt: |
Applied StemCell, a leading biotechnology company using gene editing technologies to advance innovations in biomedical research and therapeutics, today announced the appointment of leading geneticist and gene therapy pioneer, Dr. Mark A. Kay, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Kay is the Dennis Farrey Family Professor and the Associate Chair for Basic Research in the Department of Pediatrics, Professor of Genetics and the Head of the Division of Human Gene Therapy at the Stanford University’s School of Medicine. He is a leading expert in translational gene therapy and has served as the scientific advisor and sponsor-investigator for recombinant adeno-associated virus-based (rAAV) clinical trials in humans for Hemophilia B. His noteworthy contributions to the field of gene therapy also include development of viral (rAAV) and non-viral (minicircle) gene delivery systems as well as a novel gene editing approach for safe and effective targeted gene therapy; early success in rAAV-mediated treatment of hemophilia A and B, congenital blindness, and spinal muscular atrophy; and advancing RNAi and non-coding RNA biology for effective gene targeting strategies. [ABSTRACT FROM PUBLISHER] |
